Metformin mediates MicroRNA-21 regulated circulating matrix metalloproteinase-9 in diabetic nephropathy: an in-silico and clinical study

Metformin is commonly used as an oral hypoglycaemic agent in type 2 diabetes mellitus (T2DM). MicroRNA-21 is widely studied in diabetic and diabetic nephropathy (DN) patients. Matrix metalloproteinase-9 (MMP9) is involved in extracellular matrix degradation and tissue repair processes. However, the effect of metformin administration on hsa-miR-21-5p and MMP9 has not been evaluated in T2DM and DN patients. The study subjects were divided into three groups (Healthy controls = 36, T2DM = 38, DN = 35). Anthropometric measurements were taken and biochemical tests were carried out on fasting blood samples. Reverse transcriptase PCR was employed for whole blood gene expression analysis of hsa-miR-21-5p and MMP9. Bioinformatics analyses including drug-gene interaction, protein-protein interaction, functional enrichment analyses and co-expression networks were performed. In the present study, MMP9 and hsa-miR-21-5p levels were downregulated and upregulated respectively in T2DM and DN patients when compared with healthy controls. However, in metformin-treated group, a downregulation of hsa-miR-21-5p and upregulation of MMP9 was observed. In-silico analysis revealed the target genes involved in the miR-21 and MMP9 interaction network. Metformin directly targets miR-21 and regulates MMP9 expression in T2DM patients, influencing the pathogenesis of DN.HighlightsMMP-9 and hsa-miR-21-5p were downregulated and upregulated respectively in T2DM and DN patients in a Western Indian population.The patients treated with metformin showed downregulation of hsa-miR-21-5p and upregulation of MMP9.In-silico analysis revealed MMP-9 as well as PTEN to be targets of hsa-miR-21-5p.Metformin regulates MMP9 expression in T2DM and DN patient populations through hsa-miR-21-5p.

[1]  Shailja Sharma,et al.  Microrna 21 Emerging Role in Diabetic Complications: A Critical Update. , 2020, Current diabetes reviews.

[2]  S. An,et al.  Metformin ameliorates animal models of dermatitis , 2020, Inflammopharmacology.

[3]  Praveen Sharma,et al.  Perspectives on the role of PTEN in diabetic nephropathy: an update , 2020, Critical reviews in clinical laboratory sciences.

[4]  Ziquan Lv,et al.  Metformin and Its Benefits for Various Diseases , 2020, Frontiers in Endocrinology.

[5]  M. Nourbakhsh,et al.  Metformin reduces fibrosis factors in insulin resistant and hypertrophied adipocyte via integrin/ERK, collagen VI, apoptosis, and necrosis reduction. , 2019, Life sciences.

[6]  Barry Demchak,et al.  Cytoscape Automation: empowering workflow-based network analysis , 2019, Genome Biology.

[7]  G. Opdenakker,et al.  MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus , 2019, Front. Immunol..

[8]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[9]  Maria Habib,et al.  Xeno-miRNet: a comprehensive database and analytics platform to explore xeno-miRNAs and their potential targets , 2018, PeerJ.

[10]  A. Ceriello,et al.  Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability , 2018, Cardiovascular Diabetology.

[11]  Alex H. Wagner,et al.  DGIdb 3.0: a redesign and expansion of the drug–gene interaction database , 2017, bioRxiv.

[12]  Jianguo Xia,et al.  miRNet-Functional Analysis and Visual Exploration of miRNA-Target Interactions in a Network Context. , 2018, Methods in molecular biology.

[13]  F. Berrino,et al.  Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities , 2017, Cell Discovery.

[14]  Wen-Dong Li,et al.  Metformin inhibits endothelial progenitor cell migration by decreasing matrix metalloproteinases, MMP-2 and MMP-9, via the AMPK/mTOR/autophagy pathway. , 2017, International journal of molecular medicine.

[15]  Q. Wan,et al.  MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway , 2017, Scientific Reports.

[16]  M. Heuser,et al.  Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  L. Moons,et al.  Platelet-Associated Matrix Metalloproteinases Regulate Thrombus Formation and Exert Local Collagenolytic Activity , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Adam J. Yen,et al.  Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer , 2014, Oncotarget.

[19]  Lin Sun,et al.  A glimpse of matrix metalloproteinases in diabetic nephropathy. , 2014, Current medicinal chemistry.

[20]  D. Tarng,et al.  Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. , 2014, Kidney international.

[21]  U. Panzer,et al.  Leukocyte-derived MMP9 is crucial for the recruitment of proinflammatory macrophages in experimental glomerulonephritis. , 2013, Kidney international.

[22]  Jinyang Wang,et al.  Effect of miR-21 on Renal Fibrosis by Regulating MMP-9 and TIMP1 in kk-ay Diabetic Nephropathy Mice , 2013, Cell Biochemistry and Biophysics.

[23]  Philippe Dessen,et al.  Atlas of Genetics and Cytogenetics in Oncology and Haematology in 2013 , 2012, Nucleic Acids Res..

[24]  A. Lewiński,et al.  Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia , 2011, Archives of medical science : AMS.

[25]  Ki-Up Lee,et al.  AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. , 2010, Bone.

[26]  P. Pereira,et al.  Diabetes mellitus: new challenges and innovative therapies , 2010, EPMA Journal.

[27]  M. Sauter,et al.  Role of matrix metalloproteinases in viral-associated glomerulonephritis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  C. Libert,et al.  Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation , 2007, Journal of leukocyte biology.

[29]  D. Moczulski,et al.  Expression pattern of genes in peripheral blood mononuclear cells in diabetic nephropathy , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[30]  P C Trevilatto,et al.  Inhibition of human pulpal gelatinases (MMP-2 and MMP-9) by zinc oxide cements. , 2004, Journal of oral rehabilitation.

[31]  Z. Werb,et al.  Matrix Metalloproteinase 9 Protects Mice from Anti–Glomerular Basement Membrane Nephritis through Its Fibrinolytic Activity , 2001, The Journal of experimental medicine.